Neurogene Inc.
NGNE · XNASCIK 1404644fmd_0MSK1GNZMS5DA42VDF4TP44AYEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2006 to Sep 30, 2026, 62 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 25 | – | – | – | – | 0 | 1 | 0 |
| Net interest income | – | – | – | – | – | 0 | 2 | – | – | – |
| Research and development | 28 | 36 | 42 | 4 | 24 | 39 | 48 | 44 | 61 | 75 |
| Total operating expenses | 38 | 51 | 58 | 71 | – | 61 | 57 | 56 | 84 | 103 |
| Operating income | (38) | (51) | (33) | (71) | (34) | (61) | (57) | (56) | (83) | (103) |
| Interest expense | 0 | 0 | 0 | 0 | – | – | 0 | 0 | 0 | 0 |
| Interest and investment income | – | – | – | – | – | – | 1 | 3 | 8 | 12 |
| Other non-operating income (expense) | 1 | 1 | 1 | 2 | 0 | (0) | (0) | – | 7 | 13 |
| Income before taxes | (37) | (50) | (32) | (69) | (33) | (61) | (55) | (36) | (75) | (90) |
| Income tax expense | 0 | – | – | – | – | – | – | – | 0 | 0 |
| Net income from continuing operations | (37) | – | – | – | – | – | – | – | (75) | (90) |
| Net income | (37) | (50) | (32) | (69) | (33) | (61) | (55) | (36) | (75) | (90) |
| Net income to common shareholders | (37) | – | – | – | – | – | – | – | – | – |